LAVAL, Quebec, March 12, 2018 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) and Valeant Pharmaceuticals International (“VPI,” and together with Valeant, the “Offerors”), a wholly owned indirect subsidiary of Valeant, incorporated in…